Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer ...

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...

While not yet detected in high numbers, experts expect the ___ variant to become the dominant COVID strain in the U.S. over ...

Here are 10 of the best health care stocks to buy in 2024, according to CFRA analysts: *As of Sept. 10 close. Based on ...

Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free ...

Lynparza, Calquence and Truqap. At AstraZeneca, Dr. Fawell also helped build the company’s targeted protein degradation ...

Most patients with ovarian cancer are diagnosed at late stage as symptoms at early stages are minimal making it difficult to differentiate from common diseases. Once patients reach these late stages, ...

PARP inhibitor Lynparza (olaparib) is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co ...

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an ...

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...